A clinical trial with DSIP. - DSIP Study

Key Findings

Ten injections of DSIP normalized sleep in 6 out of 7 severe insomnia patients.

The sleep benefit lasted 3–7 months after treatment.

Daytime mood and performance were reported to improve alongside sleep.

A long‑standing habit of drug addiction may interfere with DSIP’s effectiveness.

Practical Outcomes

DSIP shows promise as a short‑term intervention for refractory insomnia and may boost daytime function, but the evidence is limited to a handful of cases. Anyone considering it should start with low doses, monitor sleep and mood closely, and be cautious if they have a history of substance dependence. More rigorous, controlled studies are needed before it can be recommended as a standard protocol.

Summary

In a tiny open‑label trial, seven people with very bad insomnia got ten shots of the peptide DSIP. Six of them slept normally again and kept that improvement for a few months, and they also felt better and performed better during the day. The authors note that a history of drug addiction might complicate things.

Abstract

In an open study 7 patients with severe insomnia were treated by a series of 10 injections with the delta-sleep-inducing peptide (DSIP). In all but 1 case sleep was normalized for follow-up periods of 3-7 months. The mood and performance during the daytime improved as well. A problem may be a long-standing habit of drug addiction.

Study Information

Provider

pubmed

Year

1984

DOI

10.1159/000115717

Citations